Reovirus for the treatment of cellular proliferative disorders

Details Reovirus for the treatment of cellular proliferative disorders Reovirus for the treatment of cellular proliferative disorders

2008-11-25

2011-11-29

Li, Bao (Department: 1648)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S215100

Reexamination Certificate

active

08066985

ABSTRACT:
Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.

REFERENCES:
patent: 4108983 (1978-08-01), Wallack
patent: 4490358 (1984-12-01), Greene et al.
patent: 4515777 (1985-05-01), Apontoweil et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5614403 (1997-03-01), Ramig et al.
patent: 5874531 (1999-02-01), Strominger et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 6136307 (2000-10-01), Lee et al.
patent: 6261555 (2001-07-01), Lee et al.
patent: 6344195 (2002-02-01), Lee et al.
patent: 6455038 (2002-09-01), Lee et al.
patent: 6565831 (2003-05-01), Coffey et al.
patent: 6994858 (2006-02-01), Morris et al.
patent: 7198783 (2007-04-01), Morris et al.
patent: 7264798 (2007-09-01), Coffey et al.
patent: 7431932 (2008-10-01), Morris et al.
patent: 7608257 (2009-10-01), Coffey et al.
patent: 7708987 (2010-05-01), Coffey et al.
patent: 7803385 (2010-09-01), Coffey
patent: 2007/0071723 (2007-03-01), Coffey et al.
patent: 2010/0021432 (2010-01-01), Coffey et al.
patent: 0013449 (1980-07-01), None
patent: 0101348 (1984-02-01), None
patent: 0453242 (1991-10-01), None
patent: 0514603 (1992-11-01), None
patent: 0687728 (1995-12-01), None
patent: 62055079 (1987-03-01), None
patent: 90/09441 (1990-08-01), None
patent: 90/11765 (1990-10-01), None
patent: 94/18992 (1994-09-01), None
patent: 97/16443 (1997-05-01), None
patent: 98/08541 (1998-03-01), None
patent: 99/08692 (1999-02-01), None
patent: 99/18799 (1999-04-01), None
Ahmed et al., “Genetic variation during lytic reovirus infection: high-passage stocks of wild type reovirus contain temperature sensitive mutants”Journal of Virology34:285-287 (1980).
Xing et al., “Prevention of breast cancer growth, invasion and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428”Cancer Research57:3585-3593 (1997).
Andreansky, S.S. et al., “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors,”Proc. Natl. Acad. Sci. USA 93:11313-11318 (1996).
Armstrong et al., “Studies on Reovirus Receptors of L Cells: Virus Binding Characteristics and Comparison with Reovirus Receptors of Erythrocytes”,Virology138:37-48 (1984).
Aronheim et al., “Membrane Targeting of the Nucleotide Exchange Factor Sos is sufficient for Activating the Ras Signaling Pathway”,Cell78:949-961 (1994).
Baer et al., “Mutations in reovirus outer-capsid protein selected during persistent infections of L cells confer resistance to protease inhibitor E64” Journal of Virology 71(&):4921-8 (1997).
Barbacid, M., “rasGenes,”Annu. Rev. Biochem. 56:779-827 (1987).
Berrozpe et al. “Comparative Analysis of Mutations in the p53 and K-rasGenes in Pancreatic Cancer”,Int. J. Cancer58: 185-191 (1994).
Bischoff et al., “Activation of the Human P1/eIF-2α Protein Kinase by Individual Reovirus s-Class mRNAs: s1 mRNA is a Potent Activator Relative to s4mRNA”,Virology172:106-115 (1989).
Boviatsis, E.J. et al., “Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase,”Gene Therapy1:323-331 (1994).
Bryson, J.S. and Cox, D.C., “Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia,”Cancer Immunol. Immunother. 26:132-138 (1988).
Bos, “rasOncogenes in Human Cancer: A Review”,Cancer Research49: 4682-4689 (1989).
Cahill, M.A., et al., “Signalling pathways: Jack of all cascades,”Current Biology, 6(1):16-19 (1996).
Chambers, R. et al., “Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in ascidmouse model of human malignant glioma,”Proc. Natl. Acad. Sci. USA92:1411-1415 (1995).
Chandran, Kartik et al., “Protease Cleavage of Reovirus Capsid Protein μ1/μ1C is Blocked by Alkyl Sulfate Detergents, Yielding a New Type of Infectious Subvirion Particle,”Journal of Virology, vol. 72, No. 1, pp. 467-475 (1988).
Chaubert et all, “K-rasMutations and p53 Alterations in Neoplastic and Nonneoplastic Lesions Associated with Longstanding Ulcerative Colitis”,American Journal of Pathology144:767-775 (1994).
Cuff et al., “Enteric Reovirus Infection as a Probe to Study Immunotoxicity of the Gastrointestinal Tract”,Toxicological Sciences142:99-108 (1998).
Coffey, Matthew C. et al., “Reovirus Therapy of Tumors with Activated Ras Pathway,”Science, vol. 282, No. 5392, pp. 1332-1334 (1998).
Database Biosis Online!, Biosciences Information Service, Philadelphia, PA, US; 1996, Bollag Gideon et al., “Loss of NF1 Results in Activation of the Ras Signalling Pathway and Leads to Aberrant Growth in Haematopoietic Cells,”Nature Genetics, vol. 12, No. 2, pp. 144-148 (1996).
Der et al., “A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis”,Proc Natl. Acad. Sci. USA94:3279-3283 (1997).
Dudley et al., “A synthetic inhibitor of the mitogen-activated protein kinase cascade”,Proc. Natl. Acad. Sci. USA92:7686-7689 (1995).
Duncan, M.R. et al., “Differential Sensitivity of Normal and Transformed Human Cells to Reovirus Infection,”J. of Virol. 28(2):444-449 (1978).
Duncan et al., “Conformational and functional Analysis of the C-Terminal Globular Head of the Reovirus Cell Attachment Protein”,Virology182: 810-9819 (1991).
Fields et al., “Genetic and molecular mechanisms of viral pathogenesis: implications for prevention and treatment” Nature 300:19-23 (1982).
Flamand et al., “Penetration of the nervous systems of suckling mice by mammalian reoviruses”Journal of Virology65(1):123-131 (1991).
Gale, Jr. et al., “Evidence that Hepatitis C Virus Resistance to Interferon is Mediated Through Repression of the PKR Protein Kinase by the Nonstructural 5A Protein”Virology230:217-227 (1997).
Gentsch, J.R. and Pacitti, A.F., “Effect of Neuraminidase Treatment of Cells and Effect of Soluble Glycoproteins on Type 3 Reovirus Attachment to Murine L Cells,” J. of Virol. 56 (2):356-364 (1985).
Hall-Jackson, C.A. et al., “Induction of Cell Death by Stimulation of Protein Kinase C in Human Epithelial Cells Expressing a MutantrasOncogene: A Potential Therapeutic Target,”British Journal of Cancer, vol. 78, No. 5, pp. 641-651 (1998).
Hashiro et al., “The Preferential Cytotoxicity of Reovirus for Certain Transformed Cell Lines”,Archives of Virology54(4):307-315 (1977).
He et al., “Suppression of the Phenotype ofγ134.5-Herpes Simplex Virus 1: Failure of Activated RNA-Dependent Protein Kinase to Shut Off Protein Synthesis is Associated with a Deletion in the Domain of the α47 Gene”J. of Virol. 71(8):6049-6054 (1997).
Helbing et al., “A Novel Candidate Tumor Suppressor,INGI, IS Involved in the Regulation of Apoptosis”,Cancer Research57:1255-1258, (1997).
Hershey, J.W.B., “Translation Control in Mammalian Cells,”Annu. Rev. Biochem. 60:717-755 (1991).
Hooper et al., “Role of the u1 protein in reovirus stability and capacity to cause chromium release from hosts” Journa

Affiliated with

Also associated with

Rating

Reovirus for the treatment of cellular proliferative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reovirus for the treatment of cellular proliferative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reovirus for the treatment of cellular proliferative disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4286807